Investor Presentaiton
Investor presentation
ADA 2019
Slide 34
R&D milestones in 2019
Project
TresibaⓇ
RyzodegⓇ
OzempicⓇ
Anti-IL-21
Q1 2019
US submission
(CV label update)
Q2 2019
Phase 3b results
(vs glargine U300)
CN regulatory decision ✓
FOCUS trial initiation (OT²)
FORTE initiation (dose trial)
Phase 2 results
Clinical milestones¹
Regulatory milestones¹
Q3 2019
Q4 2019
FLOW trial initiation
(Outcomes trial³)
LAI287
LAIsema
Oral semaglutide
Amylin - AM833
Tri-agonist 1706
PYY 1562
Semaglutide combination
Phase 1 initiation
US submission
US submission (CV) ✓
Phase 2 initiation
EsperoctⓇ/N8-GP
Concizumab
Somapacitan
Diabetes
Phase 2 results
Phase 1 results
SOUL trial initiation (CVOT)
EU submission
US regulatory decision
Japan submission
PoC phase 2 initiation
US regulatory decision
CHMP recommendation✓
Obesity
NASH
Phase 3 initiation
(GHD)
Haemophilia
Growth disorders
Phase 1 results
Phase 1 results
Japan regulatory decision
Phase 3 initiation
US and EU submission
(AGHD)
Japan submission
(AGHD)
1 Expected to be published in the given quarter or in the subsequent quarterly company announcement; 2 Diabetic retinopathy outcome trial; 3 Diabetes kidney disease outcome trial; GG-co-agonist in obesity phase 1 decisive results are
now expected in 2020; OT: Outcomes trial; GHD: Growth hormone deficiency; AGHD: Adult growth hormone deficiency; CVOT: Cardiovascular outcomes trial; CV: Cardiovascular; PoC: proof of concept; NASH: nonalcoholic steatohepatitisView entire presentation